The recent FLOW trial with semaglutide in patients with chronic kidney disease and T2DM, with a composite of major kidney disease events as the primary outcome, showed significant reductions in both cardiovascular mortality (HR 0.71
It does all these by facilitating the production of more growth hormone for your body
The Wegovy prescribing information specifically cautions that adverse-reaction rates from one drug's clinical trials cannot be directly compared with another drug's trial rates
Lancet Diabetes Endocrinol 7:344355 Mozaffarian D (2024) GLP-1 agonists for obesityA new recipe for success
The results show that IF could be a non-pharmacological method to improve brain health, slow down neurodegenerative processes, and potentially reduce the burden of dementia-related diseases [37, 75, 76]
This translates to a lower incidence of sunburns and damage and a lower chance of developing skin cancer